Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

October 28, 2020October 28, 2020

Opdivo Combo Found to Extend Survival in Advanced Stomach, Esophageal Cancers

News

Adding Opdivo (nivolumab) to standard first-line chemotherapy significantly extends overall survival and delays disease progression or death in adults with inoperable advanced HER2-negative stomach cancer, esophageal adenocarcinoma, or gastroesophageal junction (GEJ) cancer, ... Read more

October 23, 2020October 31, 2020

Cancer Vaccine UV1 Plus Keytruda Shows Safety, Early Efficacy in Advanced Melanoma Trial

News

Adding UV1, Ultimovacs’ experimental cancer vaccine, to Keytruda (pembrolizumab) is safe and shows initial signs of effectiveness in adults with previously untreated metastatic melanoma, according to top-line data from a Phase 1 ... Read more

September 28, 2020September 28, 2020

First-line Keytruda Doubles 5-Year Survival in Certain Lung Cancer Patients, Data Show

News

First-line treatment with Keytruda (pembrolizumab) continues to promote significant survival benefits and durable responses in people with metastatic non-small cell lung cancer (NSCLC) and high levels of PD-L1, compared with standard chemotherapy, ... Read more

September 25, 2020September 25, 2020

Tecentriq-Avastin Combo Recommended for EU Approval for Liver Cancer

News

Tecentriq (atezolizumab), in combination with Avastin (bevacizumab), has been recommended for approval in the European Union as a first-line treatment for adults with advanced hepatocellular carcinoma (HCC), the most common ... Read more

September 23, 2020September 23, 2020

EU Approval Recommended for Opdivo-Yervoy-Chemo Combo for Advanced NSCLC

News

A European Medicines Agency (EMA) committee has recommended that a combination therapy of Opdivo (nivolumab) and Yervoy (ipilimumab) plus two cycles of platinum-based chemotherapy be approved in the European Union (EU) as first-line treatment for advanced non-small ... Read more

July 28, 2020July 28, 2020

CAR T-cell Therapy Tecartus Granted FDA Approval for Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Kite Pharma’s CAR T-cell therapy Tecartus (brexucabtagene autoleucel) for adults with relapsed or refractory mantle cell lymphoma (MCL). The decision ... Read more

July 20, 2020July 20, 2020

Imfinzi Plus Chemo Aids Survival in Inoperable Pleural Mesothelioma, Phase 2 Data Show

News

Adding Imfinzi (durvalumab) to standard first-line chemotherapy prolongs survival for adults newly diagnosed with inoperable malignant pleural mesothelioma, according to data from a Phase 2 clinical trial. This study is the ... Read more

July 6, 2020July 6, 2020

First-line Tislelizumab Plus Chemo Under Review in China for Advanced NSCLC

News

The Chinese Center for Drug Evaluation (CDE) of the National Medical Products Administration has accepted for review Beigene’s application seeking approval for tislelizumab, in combination with standard chemotherapy, as a first-line treatment for ... Read more

June 18, 2020June 18, 2020

Keytruda Approved to Treat Solid Tumors With High Mutational Burden

News

The U.S. Food and Drug Administration (FDA) has conditionally approved Keytruda (pembrolizumab) for the treatment of pediatric and adult patients with inoperable or metastatic solid tumors with high tumor mutational ... Read more

June 17, 2020June 17, 2020

Bavencio Shows Benefit as 1st-line Maintenance Therapy for Bladder Cancer in Phase 3 Trial

News

First-line maintenance therapy with Bavencio (avelumab) significantly delays disease progression or death in people with inoperable, locally advanced or metastatic urothelial carcinoma, a common type of bladder cancer, according to interim data from ... Read more